New England Journal of Medicine · 1983 · 143 citations · 5 references
MedicineHematologyOncologyChemotherapyHematologic OncologyMedical OncologyChemotherapy In Hematologic MalignanciesHematologic MalignanciesHematologic Malignancy TherapyMultiple MyelomaMultiple Myeloma ChemotherapyMultiple Myeloma TherapyMultiple Myeloma Treatment
Despite the use of alkylating agents, patients with multiple myeloma have a median survival period of only two to three years.1 , 2 No series of patients with multiple myeloma surviving for more than 10 years has been reported. This review of such a group was undertaken in an effort to identify the clinical or laboratory features that suggest long-term survival. My colleagues and I found that the response to chemotherapy was the most important factor in recognizing long-term survivors.MethodsThe records of all Mayo Clinic patients given a diagnosis of multiple myeloma between January 1, 1960, and December 31, 1971 . . .
5
Combination therapy for multiple myeloma
Raymond Alexanian, Sydney E. Salmon, John D. Bonnet et al. · Cancer · 1977 · 136 citations · Full text
Medicine, Oncology, Pharmacology +16
Epibulbar IgA Plasmacytoma Occurring in Multiple Myeloma
Richard M. Franklin, Kenneth R. Kenyon, W. R. Green et al. · Archives of Ophthalmology · 1982 · 30 citations
Medicine, Immunology, Ophthalmology +13